fig5

Figure 5. From universal carrier ambitions to context-specific EV platform development. Development should begin with a defined route, tissue, or cell compartment; broader platform reuse becomes credible only after delivery and functional activity are reproducibly established. Created with BioRender. EV: Extracellular vesicle; LNPs: lipid nanoparticles; CNS: central nervous system.